AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 111 min read$IRTC

Shrishrimal Sumi sold $670K of IRTC

Shrishrimal Sumi (EVP, Chief Risk Officer) sold 5,372 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.67M total) on 2026-08-10.

Original reporting
SEC EDGAR · Shrishrimal Sumi
Published Aug 11, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
low confidence
Mentioned
$IRTC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings of the company’s EVP Chief Risk Officer.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new operational or financial guidance in the text.

03

What to watch

The article lacks context on total holdings, prior sales cadence, and whether the sale was tax-related or part of a broader personal liquidity event.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11 after-hours; sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralLow confidence
Context

Form 4 shows IRTC EVP Chief Risk Officer Shrishrimal Sumi sold 5,372 shares for about $669.6K at $124.6539 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, which often has non-informational motives; the article provides no accompanying guidance, legal, or operational change.

Market effects

Sector

No sector-level read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Public company subject of the Form 4 insider transaction disclosure.

  • insider
    Shrishrimal Sumi

    EVP, Chief Risk Officer who sold 5,372 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 7
MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

hoodline.com3 min
OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min